当前位置:首页 - 行情中心 - 川宁生物(301301) - 财务分析

川宁生物

(301301)

  

流通市值:63.88亿  总市值:230.59亿
流通股本:6.18亿   总股本:22.30亿

川宁生物(301301)财务分析

净利润 + 每股收益
------
  • 净利润(亿元)
  • 每股收益(元)

    截至第三季度实现净利润6.11亿元,每股收益0.27元。

股东权益 + 未分配利润
------
  • 股东权益(亿元)
  • 未分配利润(亿元)

    截至第三季度最新股东权益795151.00万元,未分配利润207099.31万元。

总资产 + 负债
------
  • 总资产(亿元)
  • 负债(亿元)

    截至第三季度最新总资产1033077.77万元,负债237926.77万元。

利润表
报告期2025-09-302025-06-302025-03-312024-12-31
营业总收入3,435,984,280.42,348,584,042.471,296,949,550.165,758,307,742.65
营业总成本2,650,557,983.641,753,026,754.01947,594,552.574,059,755,762.3
其他经营收益
营业利润767,936,150.29575,431,246.56353,331,784.321,687,762,925.68
利润总额751,774,796.43559,503,193.54350,002,745.911,675,091,839.31
净利润610,903,946.61454,575,661.01288,206,596.521,400,350,219.97
每股收益
其他综合收益----99,338.34
综合收益总额610,903,946.61454,575,661.01288,206,596.521,400,250,881.63
资产负债表
报告期2025-09-302025-06-302025-03-312024-12-31
流动资产:
流动资产合计4,021,681,016.893,916,481,272.984,416,378,924.564,144,223,873.54
非流动资产:
非流动资产合计6,309,096,664.56,242,823,019.616,316,164,332.276,409,356,087.63
资产总计10,330,777,681.3910,159,304,292.5910,732,543,256.8310,553,579,961.17
流动负债:
流动负债合计1,801,064,638.991,811,328,511.531,972,067,762.091,947,534,889.66
非流动负债:
非流动负债合计578,203,091.88560,994,874.93553,278,437.67689,629,227.58
负债合计2,379,267,730.872,372,323,386.462,525,346,199.762,637,164,117.24
所有者权益(或股东权益):
归属于母公司股东权益合计7,925,970,346.147,768,434,687.48,188,380,183.447,897,587,034.11
股东权益合计7,951,509,950.527,786,980,906.138,207,197,057.077,916,415,843.93
负债和股东权益合计10,330,777,681.3910,159,304,292.5910,732,543,256.8310,553,579,961.17
现金流量表
报告期2025-09-302025-06-302025-03-312024-12-31
经营活动产生的现金流量:
经营活动现金流入小计2,827,254,076.421,652,894,384.56648,163,490.344,783,112,022.39
经营活动现金流出小计2,256,312,811.111,261,410,616.16531,578,949.822,992,044,746.04
经营活动产生的现金流量净额570,941,265.31391,483,768.4116,584,540.521,791,067,276.35
投资活动产生的现金流量:
投资活动现金流入小计1,922,030,527.48961,564,551.48200,464,358.91206,184,133.59
投资活动现金流出小计2,224,002,533.451,006,564,070.41422,965,903.29312,401,377.78
投资活动产生的现金流量净额-301,972,005.97-44,999,518.93-222,501,544.38-106,217,244.19
筹资活动产生的现金流量:
筹资活动现金流入小计520,125,383.0112,935,5200806,191,920
筹资活动现金流出小计1,129,180,136.76639,692,901.2628,751,355.042,167,261,088.14
筹资活动产生的现金流量净额-609,054,753.75-626,757,381.26-28,751,355.04-1,361,069,168.14
汇率变动对现金及现金等价物的影响2,265,910.673,203,527.391,905,343.16,537,247.24
现金及现金等价物净增加额-337,819,583.74-277,069,604.4-132,763,015.8330,318,111.26
期末现金及现金等价物余额747,584,795.32808,334,774.66952,641,363.261,088,331,674.61
补充资料:
现金及现金等价物的净增加额--277,069,604.4-330,318,111.26
最新报告期:2025-10-29
研究机构分析师预测每股收益(元)更新日
2025年2026年2027年
中信证券李超0.420.490.582025-10-29
国投证券谢嘉豪0.400.470.542025-10-29
民生证券杨涛0.370.420.462025-10-28
TOP↑